Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand

References

• McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573–1619.
   PubMed Web of Science ®Google Scholar
• Hyduk A, Croft JB, Ayala C, et al. Pulmonary hypertension surveillance–United States, 1980-2002. MMWR Surveill Summ. 2005;54(5):1–28.
   PubMedGoogle Scholar
• Moledina S, Hislop AA, Foster H, et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart. 2010;96(17):1401–1406.
   PubMed Web of Science ®Google Scholar
• The Heart Association of Thailand under the Royal Patronage of H.M. the King. Thai Guideline for Diagnosis and Treatment of Pulmonary Hypertension 2013. [ cited 2013 Jun 12]. Available from: http://www.thaiheart.org/images/column_1385016166/PAH_guideline_2013.pdf.
   Google Scholar
• National Experts’ Working Group on NLEM. Specific drug therapy for pulmonary arterial hypertension. Nonthaburi: Thai Food and Drug Administration, Ministry of Public Health; 2012.
   Google Scholar
• Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493–2537.
   PubMed Web of Science ®Google Scholar
• Chen YF, Jowett S, Barton P, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess. 2009;13(49):1–320.
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–2157.
   PubMed Web of Science ®Google Scholar
• Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007;34(12):2417–2422.
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(12):2119–2125.
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39(9):1496–1502.
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322–329.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342(25):1866–1870.
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119–1123.
   PubMed Web of Science ®Google Scholar
• Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48–54.
   PubMed Web of Science ®Google Scholar
• Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093–2100.
   PubMed Web of Science ®Google Scholar
• Gatzoulis MA, Beghetti M, Galie N, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127(1):27–32.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903.
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353–359.
   PubMed Web of Science ®Google Scholar
• The Subcommittee for Development of the National List of Essential Medicines. Meeting of the Subcommittee for Development of the National List of Essential Medicine 10/2554. Laungvichenpattayakom Meeting Room, Thai Food and Drug Administration, Ministry of Public Health; 2011 Nov 28; Thailand.
   Google Scholar
• Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med. 2005;258(3):199–25.
   PubMed Web of Science ®Google Scholar
• Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. J Med Assoc Thai. 2008;91(suppl 2):S53–8.
   PubMedGoogle Scholar
• Velasco RP, Chaikledkaew U, Youngkong S, et al. Health technology assessment process guidelines in Thailand. Nonthaburi: Health Intervention and Technology Assessment Program; 2009.
   Google Scholar
• The Subcommitee for Development of the National List of Essential Medicines. The threshold at which an intervention becomes cost-effective meeting of the Subcommitee for Development of the National List of Essential Medicine 9/2007. Jainad Narendhorn Meeting Room, Thai Food and Drug Administration, Ministry of Public Health; 2007 Dec 20; Thailand.
   Google Scholar
• The Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization; 2002.
   Google Scholar
• Panichwattana W. Predictors of survival of patients with pulmonary arterial hypertension associated with congenital heart disease. Bangkok: Mahidol University; 2010.
   Google Scholar
• Ministry of Commerce Thailand. Report for Consumer Price Index of Thailand year. Bangkok: Bureau of Trade and Economic Indices; 2009.
   Google Scholar
• PPP conversion factor, private consumption The World Bank; 2010. Available from: http://data.worldbank.org/indicator/PA.NUS.PRVT.PP.
   Google Scholar
• Vijitleela A. Cost analysis of general heath check-up in public hospital: study in the National Cancer Institute [ Thesis]. Bangkok: Thammasat University; 2000.
   Google Scholar
• National Statistical Office. Per Capita Income of Population New Series by Region and Province: 1995-2012; 2012 Available from: http://service.nso.go.th/nso/web/statseries/statseries15.html.
   Google Scholar
• Brooks R. EuroQol Group. EuroQol: the current state of play. Health Policy. 1996;37:53–72.
   PubMed Web of Science ®Google Scholar
• Kind P. The EuroQol instrument; an index of health-related quality of life. Spilker B., editor. Philadelphia (PA): Lippincott-Raven; 1996.
   Google Scholar
• Tongsiri S. The Thai population-based preference scores for EQ-5D health states. Nonthaburi: Burden of Disease (BOD) Program, the Health Intervention and Technology Assessment Program (HITAP) and the International Health Policy Program (IHPP); 2009.
   Google Scholar
• Subcommittee for the National List of Essential Medicine. The appropriate threshold of medicine cost for inclusion in the list. The 9th Subcommittee Conference on the Development of the National List of Essential Medicine. Chainatnarenthorn meeting room, Thai Food and Drug Administration; 2007 Dec 20; Nonthaburi, Thailand.
   Google Scholar
• Highland KB, Strange C, Mazur J, et al. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest. 2003;124(6):2087–2092.
   PubMed Web of Science ®Google Scholar
• Wlodarczyk JH, Cleland LG, Keogh AM, et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. Pharmacoeconomics. 2006;24(9):903–915.
   PubMed Web of Science ®Google Scholar
• Garin MC, Clark L, Chumney EC, et al. Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig. 2009;29(10):635–646.
   PubMed Web of Science ®Google Scholar
• Stevenson MD, Macdonald FC, Langley J, et al. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III. Value Health. 2009;12(8):1100–1105.
   PubMed Web of Science ®Google Scholar
• Roman A, Barbera JA, Escribano P, et al. Cost effectiveness of prostacyclins in pulmonary arterial hypertension. Appl Health Econ Health Policy. 2012;10(3):175–188.
   PubMedGoogle Scholar